



IBA – ACQUISITION OF OWN SHARES

Immediate Release – January 17th, 2022

Louvain-la-Neuve, Belgium, January 17th, 2022 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on December 3rd, 2021.

Under this program, IBA has requested a financial intermediary to repurchase up to 400.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until June 30th, 2022, effective as from December 6th, 2021, to cover the remaining portion of the company’s obligations under a long term incentive plan granted to certain members of its personnel in 2021.

In the framework of this share buyback program, IBA repurchased 20.740 IBA shares on Euronext Brussels in the period from January 10th, 2022 up to and including January 14th, 2022, as follows:

Trade date	Shares purchased	Average price	Min price	Max price	Buyback amount
10-01-22	4.207	14,76 €	14,84 €	14,60 €	62.080,17 €
11-01-22	3.990	14,86 €	14,94 €	14,78 €	59.278,23 €
12-01-22	4.281	14,73 €	15,00 €	14,56 €	63.048,00 €
13-01-22	4.145	14,67 €	14,78 €	14,52 €	60.786,84 €
14-01-22	4.117	14,63 €	14,72 €	14,58 €	60.234,18 €
TOTAL	20.740	14,73 €	14,72 €	14,78 €	305.427,42 €

The total number of shares purchased under this program therefore amounts to 140.009. As a result, the current situation with respect to treasury shares (held directly by IBA SA and indirectly through its subsidiary IBA Investments SCRL) is the following:

	Shares	Voting rights
IBA Investments SCRL	51.973	51.973
IBA SA	819.634	883.003
Total - Treasury shares	871.607	934.976
Total - Issued shares	30.218.718	38.339.545
Treasury shares in %	2,88%	2,44%



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com

Contact person

IBA

Christian Matton,
Chief Legal Officer

shareholderrelations@iba-group.com